Aspirin Use After Colorectal Cancer Diagnosis Associated With Improved Survival

by Barbara Kram, Editor | August 12, 2009

(JAMA 2009;302[6]:649-659. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Aspirin as Adjuvant Therapy for Colorectal Cancer - A Promising New Twist for an Old Drug

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

Alfred I. Neugut, M.D., Ph.D., of Columbia University, New York, writes in an accompanying editorial that the results of this study are encouraging.

"In the study by Chan et al, the survival benefits of aspirin were similar in patients who received standard adjuvant chemotherapy and those who did not, and in patients with stage I and stage II disease as well as those who had stage III disease at diagnosis. Thus, aspirin may have the potential to be useful as adjuvant therapy not just for locally advanced disease but for early-stage patients as well. Further studies are needed to confirm and extend these findings, and should also investigate the use of aspirin as an agent in individuals with metastatic disease."

(JAMA 2009;302[6]:688-689.)

Back to HCB News